One in eight adults have reported taking a GLP-1 medication, either for chronic health conditions such as type 2 diabetes or for weight loss, according to a May 2024 KKF poll
Suitable for individuals seeking wellness and skin health support
*Correspondence: Haibo Li, [email protected] Chen, [email protected] These authors have contributed equally to this work This article was submitted to Genetics of Common and Rare Diseases, a section of the journal Frontiers in Genetics Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
These findings support biological delivery, but they do not establish that one form produces better clinical outcomes
GLP-1 RAs suppress NLRP3 inflammasome activation through multiple mechanisms: inhibition of priming signals via reduced NF-B activity, attenuation of reactive oxygen species generation through enhanced mitochondrial function, induction of autophagy that removes damaged mitochondria serving as inflammasome triggers, and direct interference with NLRP3-ASC interaction through PKA-mediated phosphorylation [38,39]
Yes healthcare providers commonly encourage prioritizing protein while on GLP-1 medications, because reduced appetite makes it hard to hit protein targets from food alone
